Cite
HARVARD Citation
Berinstein, N. et al. (n.d.). 356 Baseline PD-L1 expression and tumor immune infiltration is associated with clinical response in patients with r/r DLBCL treated with DPX-Survivac, low-dose cyclophosphamide and pembrolizumab. Journal for immunotherapy of cancer. p. A381. [Online].